

## Session 2: Determining Potency of Immunologic Therapy

- If immune “drug” potency is defined as an immune outcome- what parameters should be used to define potency?
  - (*ex vivo* function or *in vivo* activity? What are we measuring against?)
- Is there one assay that should be performed on all studies to help define “potency” *in vivo*?
  - e.g. ELISPOT, polyfunctional T cells by flow cytometry
  - Quality vs. quantity
- What are key assays to measure product potency *ex vivo*?
  - e.g. for infused T cells, NK cells, DC vaccines